Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy?

Zheng, F.; Guan, Y.
December 2007
Kidney International;Dec2007, Vol. 72 Issue 11, p1301
Academic Journal
Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for diabetic renal complications are urgently needed. Miyazaki et al. report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor γ agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. These findings could offer a new prevention of diabetic nephropathy in insulin-resistant diabetic patients.Kidney International (2007) 72, 1301–1303. doi:10.1038/sj.ki.5002557


Related Articles

  • Regression of glomerular injury by losartan in experimental diabetic nephropathy. Teles, Flávio; Machado, Flávia G.; Ventura, Bianca H.; Malheiros, Denise M. A. C.; Fujihara, Clarice K.; Silva, Luís F. F.; Zatz, Roberto // Kidney International;Jan2009, Vol. 75 Issue 1, p72 

    Many features of chronic kidney disease may be reversed, but it is unclear whether advanced lesions, such as adhesions of sclerotic glomerular tufts to Bowman's capsule (synechiae), can resolve during treatment. We previously showed, using a renal ablation model, that the renoprotective effect...

  • Cumulative Risk, Age at Onset, and Sex-Specific Differences for Developing End-Stage Renal Disease in Young Patients With Type 1 Diabetes. Möllsten, Anna; Svensson, Maria; Waernbaum, Ingeborg; Berhan, Yonas; Schön, Staffan; Nyström, Lennarth; Arnqvist, Hans J.; Dahlquist, Gisela // Diabetes;Jul2010, Vol. 59 Issue 7, p1803 

    OBJECTIVE--This study aimed to estimate the current cumulative risk of end-stage renal disease (ESRD) due to diabetic nephropathy in a large, nationwide, population-based prospective type 1 diabetes cohort and specifically study the effects of sex and age at onset. RESEARCH DESIGN AND...

  • Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Breyer, Julia A.; Bain, Raymond P.; Evans, Joni K.; Nahman Jr., N. Stanley; Lewis, Edmund J.; Cooper, Melisa; McGill, Janet; Berl, Tomas // Kidney International;Nov1996, Vol. 50 Issue 5, p1651 

    We designed a prospective, double-blind controlled trial to determine predictors of loss of renal function in patients with insulin dependent diabetes and established nephropathy. A total of 409 insulin-dependent diabetic patients with established nephropathy enrolled in a trial on the effect of...

  • Diabetes Management Issues for Patients With Chronic Kidney Disease. Cavanaugh, Kerri L. // Clinical Diabetes;Summer2007, Vol. 25 Issue 3, p90 

    The article discusses the association between diabetes and chronic kidney disease (CKD). For 45% of patients who receive dialysis therapy, diabetes is the primary cause of their kidney failure. Moderate to severe CKD is estimated to be found in 15-23% of patients with diabetes. Management of...

  • High glucose and renin release: the role of succinate and GPR91. Peti-Peterdi, János // Kidney International;Dec2010, Vol. 78 Issue 12, p1214 

    Diabetes mellitus is the most common and rapidly growing cause of end-stage renal disease. A classic hallmark of diabetes pathology is the activation of the intrarenal renin-angiotensin system (RAS), which may lead to hypertension and renal tissue injury, but the mechanism of RAS activation has...

  • Association of microsatellite markers on chromosomes 6q27 region and 10p15 region with end-stage renal disease in a UK renal transplant population. Currie, Diane; McKnight, Amy Jayne; Patterson, Christopher C.; Martin, Rosalind J. L.; Middleton, Derek; Courtney, Aisling E.; Maxwell, Alexander P. // Journal of Human Genetics;Aug2009, Vol. 54 Issue 8, p497 

    The article discusses a study on the association of microsatellite markers on chromosomes 6q27 region and 10p15 region with end-stage renal disease in renal transplant population in Great Britain. A genome-wide screen highlighted several markers associated with advanced renal failure secondary...

  • The incidence of end-stage renal disease in India: A population-based study. Modi, G. K.; Jha, V. // Kidney International;Dec2006, Vol. 70 Issue 12, p2131 

    Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are emerging public health problems in developing countries, and need changes in health-care policy. ESRD incidence data are not available from large parts of the developing world including South Asia. We report the ESRD incidence...

  • New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy. Zhanjun Jia; Ying Sun; Guangrui Yang; Aihua Zhang; Songming Huang; Heiney, Kristina Marie; Yue Zhang // PPAR Research;2014, p1 

    Diabetic nephropathy (DN) is a severe complication of diabetes and serves as the leading cause of chronic renal failure. In the past decades, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) based first-line therapy can slow but cannot stop the progression...

  • Renoprotectrve Effects of Reconstructed Composition of Trigonella foenum-graecum L. Seeds in Animal Model of Diabetic Nephropathy with and without Renal Ischemia Reperfusion in Rats. Arora, Sachin; Bodhankar, Subhash L.; Mohan, V.; Thakurdesai, Prasad A. // International Journal of Pharmacology;2012, Vol. 8 Issue 5, p321 

    Diabetic nephropathy is the kidney complication of diabetes mellitus and leading to end stage renal disease. In the past, reconstructed antidiabetic combination from Trigonellafoenum-graecum (fenugreek) seeds (IND01) containing 4-hydroxyisoleucine (40%), trigonelline (30%) and galactomannan...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics